An Open-Label Treatment Use Protocol for Daratumumab in Subjects with Multiple Myeloma Who Have Received at Least 3 Prior Lines of Therapy (Including a Proteasome Inhibitor and an Immunomodulatory Agent) or are Double Refractory to a Proteasome Inhibitor and an Immunomodulatory Agent

ID Number 15-1307

Principal Investigator(s)
Ajai Chari

Department(s) or Division(s)
Hematology and Medical Oncology


The objective of this study is to provide early access to daratumumab treatment and collect additional safety data.  Daratumumab is not approved for use by the U.S. Food and Drug Administration (FDA) or any Regulatory Authority in the European Economic Area (EEA), Eastern Europe, Russia, Asia or any other country.

Contact Information
Lisa La
(212) 241-8615

Recruiting Patients: No